Sinoxal

Quick links to important sections

Sinoxal

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sinoxal

What is Sinoxal?

Sinoxal is a medicinal product designed to address symptoms associated with inflammatory and infectious conditions of the upper respiratory tract. It is frequently utilized in the management of sinusitis, rhinitis, and other related disorders of the paranasal sinuses.

Mechanism of Action

The formulation typically combines active ingredients that work through multiple physiological pathways:

  • Mucolytic Action: It aids in thinning and liquefying dense or viscous mucus, facilitating its clearance from the nasal passages and sinus cavities.
  • Anti-inflammatory Effects: It helps reduce the swelling of the mucous membranes, which can improve airflow and drainage.
  • Decongestant Properties: By narrowing the blood vessels in the nasal lining, it assists in relieving the sensation of nasal pressure and blockage.

Therapeutic Purpose

The primary objective of Sinoxal is to restore the normal ventilation and drainage of the sinuses. By thinning secretions and reducing tissue inflammation, it helps alleviate common symptoms such as:

  • Facial pain and pressure
  • Nasal congestion
  • Difficulty breathing through the nose
  • Post-nasal drip

Sinoxal is characterized by its focus on symptomatic relief and the restoration of the physiological function of the respiratory mucosa. It is often used as part of a broader therapeutic approach to manage both acute and chronic sinus-related issues.

Regulatory References

  1. NIH LiverTox: Oxaliplatin
  2. StatPearls: Cancer Chemotherapy - Alkylating Agents
  3. WHO Essential Medicines List (eEML): Oxaliplatin

What side effects are possible with Sinoxal?

Possible side effects and safety information

The safety profile of Sinoxal (Oxaliplatin) is formally documented by regulatory agencies and is characterized by adverse reactions associated with platinum-based cytotoxic agents. These effects are organized into categories based on the physiological systems affected and their frequency of occurrence, strictly as documented in official government prescribing information.

High-Frequency Adverse Reactions

The regulatory classification lists several effects as Very Common (occurring in ge 1 out of 10 patients). These frequently involve the Gastrointestinal System, including nausea, vomiting, diarrhoea, and stomatitis. Effects on the Blood and Lymphatic System, such as anaemia, neutropenia, and thrombocytopenia (myelosuppression), are also classified as very common.

Neurological and Time-Related Safety Patterns

A defining safety characteristic is peripheral sensory neuropathy (a disorder of the Nervous System). Regulatory documents distinguish this effect based on timing: acute neuropathy often presents hours after administration and is usually transient, while the risk of chronic, persistent neuropathy is associated with the cumulative dose and long-term exposure to the medicine. Hypersensitivity reactions may also become more frequent after multiple treatment cycles.

Serious Adverse Reactions and Constraints

The official safety profile highlights potentially severe events, including Grade 3/4 myelosuppression, severe anaphylactic reactions, and rare but serious pulmonary effects like interstitial lung disease. Use of Sinoxal is formally constrained and is contraindicated in individuals with severe pre-existing myelosuppression or established peripheral sensory neuropathy accompanied by functional impairment, as defined in regulatory labeling. Safety notes also state that dose adjustments are required for patients with moderate-to-severe renal impairment.

Overdose and Emergency Response

The official regulatory profile for Sinoxal overdose documents the exacerbation of the medicine’s systemic cytotoxic effects. Documented overdose presentations include severe hematologic toxicity, such as Grade 4 thrombocytopenia, and profound gastrointestinal disorders like severe nausea and stomatitis. Neurological manifestations may be acutely exaggerated, presenting as severe sensory neuropathy, laryngospasm, and facial muscle spasms.

Life-threatening outcomes officially associated with overdose exposure involve severe myelosuppression, fatal anaphylactic reactions, and the potential for serious cardiac events, including QT interval prolongation and ventricular arrhythmias. Furthermore, regulatory labels note that overdose can result in complications such as rhabdomyolysis and hemorrhage.

Immediate medical help is required for specific, life-threatening symptoms, including collapse, seizure, unresponsiveness, or trouble breathing. Urgent attention is also mandated for any signs of severe allergic reaction, such as swelling of the tongue or difficulty swallowing. The official regulatory stance on overdose management is the administration of appropriate supportive and symptomatic treatment, as no specific pharmacologic antidote is known. This toxicity risk is officially noted to be increased in patients with kidney disease due to slower drug clearance.

Therapeutic Uses of Sinoxal

What Sinoxal Treats: Main Uses and Benefits

Sinoxal is applied across domains where additional symptomatic support is needed. It is considered relevant for short-term symptomatic management in acute or disruptive symptom patterns. Symptoms like nasal congestion and facial pain can appear suddenly or intensify over time.


Addressing Episodic Symptom Intensification

Sinoxal is commonly used to help manage symptom clusters that may become intense or disruptive. The medication is applied during phases of increased distress or discomfort. It provides support that helps ease the overall symptom burden. Sinoxal is generally relevant for easing symptoms related to physical discomfort, such as headache or fatigue.

Quick Fact: May assist with Nasal Congestion


Managing Symptom Clusters and Functional Strain

Sinoxal is applicable in conditions characterized by episodic or fluctuating manifestations. It assists with managing multiple symptoms that occur together, which supports general well-being during symptomatic phases. The therapeutic relevance includes addressing symptoms related to physical discomfort, nasal congestion, and facial pain/pressure.


Supportive Management in Common Scenarios

This medication is used for symptomatic relief across conditions presenting with acute or disruptive episodes, and when supportive symptomatic assistance is needed. It is relevant for easing symptoms, which helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

  1. NIH StatPearls on Acute Sinusitis

Eligibility and Restrictions for Use

Eligibility for Sinoxal (Oxaliplatin)

Sinoxal is indicated for use in adult patients only. Eligibility is strictly defined by regulatory documents, which establish absolute contraindications and specific population limitations. The medicine must be administered in specialized oncology settings under the supervision of a physician experienced in cancer chemotherapy.


Contraindicated Populations (Must Not Use)
Patients with known hypersensitivity to Oxaliplatin or other platinum compounds.
Women who are breastfeeding (lactation is an absolute contraindication).
Patients with severe renal impairment (creatinine clearance <30 mL/min).
Patients with pre-existing myelosuppression (neutrophils <2 imes 10^9/ L and/or platelet count <100 imes 10^9/ L) before the first course.
Patients with pre-existing peripheral sensory neuropathy with functional impairment.

Restricted or Limited Use (Requires Special Consideration)
Pediatric Population: Use is not established as safety and efficacy have not been demonstrated in children.
Pregnancy: Not recommended; Sinoxal can cause fetal harm. Female patients must use effective contraception for 9 months after treatment, and male patients for 6 months.
Older Adults (ge 65 years): No specific dose adaptation is required based on age alone.
Mild to Moderate Renal Impairment: Use is permitted, but patients must be closely monitored for toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Sinoxal identifies specific drug-drug, timing, and substance restrictions that define its co-administration framework.

Formal Interaction Classifications

Interaction Type Regulatory Restriction or Finding
Contraindicated Combinations Co-administration is formally restricted with medicines known to significantly prolong the QTc interval (e.g., Pimozide). Use with live-attenuated vaccines is also prohibited due to the risk of serious infection.
Pharmacodynamic Risk Requires close monitoring when co-administered with oral anticoagulants (e.g., Warfarin) due to a documented risk of hemorrhage. Monitoring is also required for nephrotoxic drugs due to the potential for additive organ toxicity.
Pharmacokinetic Finding No interaction is anticipated with medications affecting CYP450 enzymes. The drug may increase the systemic exposure of Fluorouracil (5-FU), and nephrotoxic drugs may potentially decrease the clearance of platinum-containing species.

Administration Restrictions

Sinoxal is subject to mandatory physicochemical incompatibility rules. The concentrate must not be diluted using sodium chloride solution or any other chloride-containing solutions. Furthermore, the medicine must not be mixed or administered simultaneously with alkaline medications or media, such as basic solutions of Fluorouracil, due to the potential for chemical degradation.

Mechanism of Action

How Sinoxal Works: Mechanism of Action


Covalent Cross-linking of DNA

Sinoxal (Oxaliplatin) exerts its primary action by forming covalent bonds with the DNA in rapidly dividing cells, particularly at Guanine residues. These chemical bonds create Pt-DNA adducts that block the progression of enzymes like DNA Polymerase, inhibiting DNA replication and transcription . This genetic damage activates the apoptotic pathway, leading to the programmed death of the affected cell, which represents the consequence of DNA damage.


Mechanistic Synergy and Repair Pathway Interaction

The mechanistic domain involves the drug's interaction with cellular DNA repair systems and other active agents. The chemical structure of the drug's adducts, featuring the DACH ligand, helps them partially evade recognition and removal by the cell's DNA Mismatch Repair ( MMR) system, contributing to the persistence of the cytotoxic effect. Furthermore, it can enhance the activity of 5-Fluorouracil (5-FU) by inhibiting Dihydropyrimidine Dehydrogenase ( DPD), which alters the metabolism of the partner drug.


Modulation of Sensory Nerve Excitability

Distinct from its DNA-damaging role, Oxaliplatin also acts as a modulator of the peripheral somatosensory system. It directly interacts with and alters the function of Voltage-Gated Sodium Channels ( Na^+ Channels) on the sensory neuron membranes. This action changes the ion flow and neural signaling threshold, resulting in neuronal hyperexcitability, a change in sensory nerve signaling.

Dosage and Administration Information

How to Use Sinoxal: Official Administration Guidelines

Sinoxal (oxaliplatin) is a prescription-only medicine administered solely by intravenous (IV) infusion under the supervision of a physician experienced in chemotherapy. The correct use of this medicine is defined by strict protocols concerning dose calculation, scheduling, preparation, and administration conditions.

Administration and Dosage Protocol

The standard initial dose is calculated based on the patient’s body surface area (BSA), typically 85 mg/m^2 on Day 1 of each cycle. Sinoxal is administered as part of a combination regimen, usually with 5-fluorouracil (5-FU) and leucovorin.

Usage Parameter Official Labeled Instruction
Route & Duration Administered by IV infusion over 120 minutes (2 hours), extendable to 6 hours if necessary.
Frequency & Cycles Administered every two weeks (q2w). Adjuvant treatment is typically 12 cycles total (6 months).
Preparation Rule Must be diluted only with 5% Dextrose Injection; chloride-containing solutions, such as saline, are prohibited for dilution or co-administration.
Sequence of Infusion The Sinoxal infusion must always precede the administration of 5-FU.

Population-Specific Dosing

Official labeling specifies dose modifications for certain populations. For patients with severe renal impairment (creatinine clearance less than 30 mL/min), the initial recommended dose is reduced to 65 mg/m^2. No general starting dose adjustment is typically required for older adults based on age alone.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Clinical Trials

Studies investigated the compound, Sinoxal, as a treatment to explore whether it might influence symptom severity in patients with Condition Y. Research explored the compound's activity in laboratory and animal models. Clinical studies assessed whether the compound had an influence on inflammation markers. Data on absorption were also collected, with studies examining whether taking the compound with food influenced its uptake in the body.


Key Efficacy Findings

Phase 3 Randomized Controlled Trial (RCT)

A pivotal Phase 3 RCT enrolled 500 participants with Condition Y. The trial examined whether the study group receiving Sinoxal experienced a difference in the primary endpoint, which was defined as a 50% reduction in the Z scale after 12 weeks of use. The study evaluated whether the number of participants reaching this endpoint differed between the Sinoxal group and the placebo group.

  • One randomized controlled trial compared the results of Sinoxal to standard care.
  • The research team investigated the rates of symptom recurrence in the six months following treatment completion.

Long-term Extension Study

An open-label extension study monitored 200 of the original trial participants for up to two years. The main objective was to collect data on the occurrence of adverse events during the extended study period and assess whether changes in Z scale scores were maintained over the study duration. Findings were collected on the participants’ quality of life scores throughout the study.


Safety and Tolerability Profile

In clinical trials, researchers monitored for adverse events to describe the full spectrum of side effects. The most commonly reported adverse events across all phases were noted as nausea, headache, and fatigue.

  • Gastrointestinal Effects: Studies examined whether a higher incidence of gastrointestinal events, such as diarrhea, was observed in the treatment group compared to the control group.
  • Liver Impairment: Studies of patients with liver impairment were conducted to examine potential changes in the drug’s metabolism. Research evaluated dose modifications and monitored outcomes in this patient population.
  • Serious Adverse Events (SAEs): Across the clinical development program, researchers tracked the incidence of SAEs. The rate of SAEs was compared between the Sinoxal treatment groups and the control groups.

Key Studies & References

  1. Efficacy and Safety of Sinoxal in Patients with Condition Y: A Phase 3 Randomized, Placebo-Controlled Trial (Trial Identifier: XYZ-123)
  2. Clinical Guidance for the Management of Condition Y (National Clinical Guideline)

Frequently Asked Questions (FAQ)

Common questions about Sinoxal (FAQ)


Q: What is the main difference between Sinoxal and [similar drug]?

Sinoxal (Oxaliplatin) is formally classified as a third-generation platinum complex. Official product information highlights its specific chemical structure, which includes a distinct ligand (DACH) compared to older agents. This structure is described as helping the compound evade detection by certain cellular repair systems, which contributes to its unique pharmacological profile.


Q: Is Sinoxal considered a narcotic?

No. According to authoritative sources, Sinoxal (Oxaliplatin) is categorized as an antineoplastic agent, meaning it is a type of chemotherapy drug used to manage malignant tumors. It is not classified as a narcotic or a controlled substance.


Q: Does Sinoxal make you feel dizzy?

Official safety documents list dizziness and temporary visual disturbances as reported side effects. Regulatory warnings state that if these symptoms occur, operating machinery or driving should be avoided.


Q: Is it true that Sinoxal can cause weight gain?

Clinical trials and official documents list changes in body weight as reported adverse events. This includes both instances of weight gain (increased weight) and weight loss (decreased weight). These changes are noted among the general spectrum of effects monitored by researchers.


Q: How long does the effect of Sinoxal last in the body?

Regulatory documents describe the movement and breakdown of the medicine in the body (pharmacokinetics). The platinum compounds derived from Sinoxal are cleared from the blood over a prolonged period. They have a long terminal elimination half-life, indicating the substance’s significant clearance time.


Q: Are there generic versions of Sinoxal available?

Yes, the active ingredient, Oxaliplatin, is available in generic form as a concentrate for injection from various manufacturers. The original brand name product for the medicine is Eloxatin.


Q: Does Sinoxal have any warnings about driving or operating machinery?

Yes. Official safety documents include a specific warning stating that Sinoxal may cause visual disturbances or dizziness. Regulatory documents state that driving or operating heavy machinery should be avoided if patients experience these effects.


Q: What is the maximum amount of time someone can take Sinoxal?

The recommended maximum duration of use depends on the condition being addressed. For adjuvant treatment (treatment following primary therapy), the total course is typically 12 cycles over approximately 6 months. For metastatic disease, the medicine is administered every two weeks until unacceptable side effects or disease progression occurs.


Q: Is Sinoxal safe to take if I have liver problems?

Clinical studies have investigated the use of the medicine in patients with liver impairment. Research findings indicate that dose reductions are generally not indicated for single-agent use based on the degree of liver dysfunction alone. Regulatory information indicates that monitoring may still be required in individuals with liver impairment.


Q: Can Sinoxal interact with common pain relievers like ibuprofen?

The official label advises general caution regarding co-administration with nephrotoxic products, which are drugs known to potentially harm the kidneys. Since some common pain relievers (such as NSAIDs) can affect kidney function, co-administration may require monitoring due to the potential for additive toxicity.


Q: What should I do if I think I'm having an allergic reaction to Sinoxal?

Regulatory guidance highlights that signs of a severe hypersensitivity or allergic reaction, such as difficulty breathing, chest tightness, wheezing, or feeling faint, require immediate medical evaluation. Severe reactions, including anaphylaxis, have been highlighted by regulators as a risk.


Q: Are there any dietary supplements that interact with Sinoxal?

Regulatory guidance universally advises patients to disclose all products they are using to their treatment team. This comprehensive disclosure is necessary to manage the risk of potential interactions with chemotherapy agents, including prescription medicines, vitamins, and supplements.


Q: Is Sinoxal gluten-free?

The official ingredients list for the liquid concentrate for infusion primarily contains the active ingredient, water, tartaric acid, and sodium hydroxide. Lactose monohydrate is a common excipient in the freeze-dried (lyophilized) forms. Official documents provide a complete list of components.


Q: Can I take Sinoxal if I have diabetes?

The medicine is required to be diluted only with a 5% Dextrose Injection, which contains glucose. Furthermore, official safety data lists hyperglycemia (high blood sugar) as a potential adverse effect monitored in clinical trials, suggesting a potential impact on glucose management.


Q: Is Sinoxal commonly used in other countries?

Yes. The active ingredient, Oxaliplatin, is globally recognized. It is included on the World Health Organization’s List of Essential Medicines, which confirms its status as a widely adopted, standard treatment.


Q: What if Sinoxal doesn't seem to be working for me?

Treatment protocols are designed for regular clinical review. If patients experience persistent issues or side effects, regulatory guidelines specify that the treatment team may consider dose reductions or treatment delays for subsequent cycles.


Q: How soon after stopping Sinoxal can I resume normal activities?

Official regulatory guidelines define a prolonged clearance period, particularly regarding reproductive safety. Both male and female patients and their partners are noted as needing to use contraception for many months (up to 9 months for females) following the last dose, indicating the substance’s significant and prolonged systemic presence.


Q: How is Sinoxal eliminated from the body?

After administration, the active platinum compounds are removed from the body primarily through the kidneys (renal excretion). Official pharmacokinetic data shows that approximately 54% of the platinum administered is cleared in the urine within the first five days.


Q: Does the packaging of Sinoxal contain any special safety alerts?

Yes, the official US label includes a Boxed Warning (also known as a Black Box Warning). This is used by the regulator to highlight the risk of potentially severe adverse reactions, such as the possibility of life-threatening hypersensitivity reactions, including anaphylaxis.

How should Sinoxal be stored and disposed of?

Sinoxal (Oxaliplatin) is a cytotoxic concentrate that requires strict adherence to official storage and disposal regulations to maintain its stability and manage risk.


Storage Requirements

Condition Specification (as per Labeled Instructions)
Temperature Store at controlled room temperature, 25^circmathrmC (77^circmathrmF). Brief excursions are allowed between 15^circmathrmC and 30^circmathrmC
Prohibited Do not refrigerate or freeze the concentrate solution.
Protection Store the vial in the original outer carton to protect the contents from light.
Child Safety Keep out of the sight and reach of children.

Handling and Disposal

The medicine's classification requires specific handling and disposal protocols. Preparation must adhere to procedures for cytotoxic products. Unused medicine, vials, and contaminated materials must not be thrown into wastewater or household waste. Disposal must strictly follow local cytotoxic waste disposal regulations for antineoplastic agents.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sinoxal found in:

A-Z Index: